We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


Phase II melanoma study with SCIB1 to start in Q219

Lighthouse | 25 April 2019


At the forefront of the cell therapy revolution

Update | 24 April 2019

Mereo BioPharma

Path cleared for partnering of acumapimod (BCT-197)

Lighthouse | 16 April 2019

Hutchison China MediTech

Proposed listing in Hong Kong and global offering

Lighthouse | 15 April 2019

Hutchison China MediTech

AACR 2019: Savolitinib in the spotlight in NSCLC

Update | 09 April 2019


Efficacy endpoint met in Phase II AML study

Lighthouse | 02 April 2019


Further support for bemcentinib’s broad potential from preclinical data at AACR

Lighthouse | 01 April 2019


Terms of the rights issue announced

Lighthouse | 28 March 2019

Hutchison China MediTech

Bringing Global Innovation and China Oncology into focus

Update | 21 March 2019


Securing the commercial future of NBT in depression

Update | 18 March 2019
1 2 3 4 5 6 7 8 9 10 11
110 results found.